Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

High-dose melphalan-autologous hematopoietic cell transplantation in systemic AL amyloidosis following daratumumab-based frontline therapy

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

References

  1. Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 2021;385:46–58.

    Article  CAS  PubMed  Google Scholar 

  2. D’Souza A, Dispenzieri A, Wirk B, Zhang M, Huang J, Gertz MA, et al. Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a Center for International Blood and Marrow Transplant Research Study. J Clin Oncol. 2015;33:3741.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Kastritis E, Minnema MC, Dimopoulos M, Merlini G, Theodorakakou F, Fotiou D, et al. Efficacy and safety of daratumumab monotherapy in newly diagnosed patients with stage 3B light chain amyloidosis: a phase 2 study by the European Myeloma Network. Blood. 2021;138:2730.

    Article  Google Scholar 

  4. Palladini G, Kastritis E, Maurer MS, Zonder J, Minnema MC, Wechalekar AD, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood. 2020;136:71–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Lentzsch S, Lagos GG, Comenzo RL, Zonder JA, Osman K, Pan S, et al. Bendamustine with dexamethasone in relapsed/refractory systemic light-chain amyloidosis: results of a phase II study. J Clin Oncol 2020;38:1455.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Seldin DC, et al. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017;130:597–605.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Sanchorawala V, Shelton AC, Lo S, Varga C, Sloan JM, Seldin DC. Pomalidomide and dexamethasone Win the treatment of AL amyloidosis: results of a phase 1 and 2 trial. Blood. 2016;128:1059–62.

    Article  CAS  PubMed  Google Scholar 

  8. Chakraborty R, Bhutani D, Maurer MS, Mohan M, Lentzsch S, D’souza A. Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis. Blood Cancer J. 2023;13:172.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Forgeard N, Elessa D, Carpinteiro A, Belhadj K, Minnema M, Roussel M, et al. Teclistamab in relapsed or refractory AL amyloidosis, a multinational retrospective case series. Blood J. 2024;143:734–7.

  10. Hammons L, Szabo A, Janardan A, Bhatlapenumarthi V, Annyapu E, Dhakal B, et al. The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma. Haematologica. 2024;109:906–14.

  11. Gustine JN, Staron A, Szalat RE, Mendelson LM, Joshi T, Ruberg FL, et al. Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25‐year longitudinal study. Am J Hematol. 2022;97:1189–99.

    Article  PubMed  Google Scholar 

  12. Staron A, Burks EJ, Szalat RE, Sanchorawala V. Prospective Evaluation of Measurable Residual Disease (MRD) and Sustainability of the Response in Patients with Systemic AL Amyloidosis Treated with Daratumumab. Blood. 2023;142:3405.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Contributions

GSM, MYM, and RC conceived the study design. GSM collected patient data from electronic medical records. DB, MYM, MSM, JR, SL, and RC performed patient care. GSM wrote the first draft of the manuscript. DB, MYM, MSM, JR, SL, and RC critically reviewed the first draft and approved the final draft of the manuscript.

Corresponding author

Correspondence to Rajshekhar Chakraborty.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mellgard, G.S., Bhutani, D., Mapara, M.Y. et al. High-dose melphalan-autologous hematopoietic cell transplantation in systemic AL amyloidosis following daratumumab-based frontline therapy. Bone Marrow Transplant (2024). https://doi.org/10.1038/s41409-024-02301-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41409-024-02301-7

Search

Quick links